Pharmaceuticals · 2022
Sequence evidence
RWLRGLLSGLLRRLLSGLLL
Table 1: DFTavP1 sequence RWLRGLLSGLLRRLLSGLLL, length 20, net charge +5, hydrophobic content 55%.
Experimental observations
Section 2.1: DFTavP1 showed an 18% higher inhibition than LL-37 at 2.5 µM (Figure 4).
Section 2.3: DFTavP1 displayed 69% inhibition at 2.5 µM when treated immediately after infection (Figure 5A).
Section 2.3: DFTavP1, in the 4 h postinfection treatment study, showed a major decrease of 54% inhibition at 5 µM.
Table 2: DFTavP1 MIC 8–16 µM against S. aureus USA300.
Table 2: DFTavP1 MIC 8–16 µM against S. epidermidis 1457.
Table 2: DFTavP1 MIC 16 µM against E. coli E416-7.
Table 2: DFTavP1 MIC 32 µM against P. aeruginosa #2.
Table 2: DFTavP1 MIC 16–32 µM against K. pneumoniae E406-17.
Table 2: DFTavP1 MIC 8 µM against A. baumannii B28-16.
Table 3: DFTavP1 hRBC HC50 <12.5 µM.
Table 3: DFTavP1 mRBC HC50 <10 µM.
Table 3: DFTavP1 HaCaT TC50 25 µM.
Table 3: DFTavP1 Vero Cell TC50 2.39 µM.
Table 3: DFTavP1 Calu3 Cell TC50 11.88 µM.
Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.
